FDA Grants Priority Review for Takeda (TAK) and Protagonist’s Rusfertide in PV Treatment

Core Insights - Takeda Pharmaceutical Company Limited (NYSE:TAK) is recognized as a promising stock under $20, particularly following the FDA's acceptance of the New Drug Application for rusfertide, a first-in-class hepcidin mimetic aimed at treating polycythemia vera, a rare blood cancer [1][4] Regulatory Developments - The FDA has granted Priority Review for rusfertide, with a Prescription Drug User Fee Act action date set for Q3 2026, indicating the drug's potential to meet significant unmet medical needs [2] - The regulatory submission is backed by data from the Phase 3 VERIFY study and long-term results from Phase 2 REVIVE and THRIVE trials, which demonstrated that rusfertide significantly improved response rates when added to standard care [2] Clinical Efficacy - Clinical findings revealed that rusfertide more than doubled response rates compared to standard treatments alone, with key benefits including sustained control of hematocrit levels below 45%, reduced need for phlebotomy procedures, and improvements in patient-reported symptoms like fatigue [2][3] Collaboration and Commercialization - Under a 2024 collaboration agreement, Takeda is responsible for the regulatory strategy and global filings, while Protagonist Therapeutics retains an option to co-commercialize rusfertide in the US through a profit-sharing model [3] - Rusfertide functions by mimicking the hormone hepcidin to regulate iron homeostasis, targeting the disease's underlying mechanism, and if approved, it will offer a novel subcutaneous treatment option for patients [3]